Fibrosarcoma — a spindle-cell sarcoma of fibroblastic differentiation that, in its modern molecular classification, encompasses two biologically and clinically distinct entities whose treatment paradigms, prognoses, and molecular characteristics differ so profoundly that they require separate clinical and technological frameworks: adult fibrosarcoma (a rare high-grade malignancy that represents a diagnosis of exclusion in contemporary sarcoma pathology, established only after immunohistochemical and molecular studies have excluded other spindle-cell sarcoma diagnoses including synovial sarcoma, MPNST, dedifferentiated liposarcoma, solitary fibrous tumor, leiomyosarcoma, and undifferentiated pleomorphic sarcoma, occurring predominantly in middle-aged to older adults in the extremities and trunk, carrying a 5-year overall survival of approximately 40–60% for localized disease with standard surgical resection and adjuvant therapy, and treated with anthracycline-based chemotherapy — doxorubicin monotherapy or doxorubicin/ifosfamide combination — for locally advanced or metastatic disease) and infantile/congenital fibrosarcoma (a congenital or early childhood soft tissue tumor defined by the pathognomonic ETV6-NTRK3 fusion gene resulting from t(12;15)(p13;q25) chromosomal translocation, occurring predominantly in the distal extremities — particularly the foot, ankle, and forearm — of children younger than two years, carrying an excellent prognosis with 5-year overall survival exceeding 90% when treated with modern NTRK inhibitor therapy, and historically managed with neoadjuvant chemotherapy using vincristine, actinomycin-D, and cyclophosphamide [VAC] or vincristine/ifosfamide/actinomycin-D [VIA] regimens to reduce tumor size before limb-sparing surgery, now being increasingly managed with larotrectinib or entrectinib as primary systemic therapy given the dramatic response rates — exceeding 75–80% — in NTRK fusion-positive tumors). The molecular landscape of adult fibrosarcoma involves heterogeneous genetic alterations without a defining molecular signature — recurrent findings include CDK4 amplification (identified in a subset of cases, with potential therapeutic implications for CDK4/6 inhibitor therapy), TP53 mutations, complex karyotypic abnormalities, and occasional NF1 mutations — while infantile fibrosarcoma's defining ETV6-NTRK3 fusion generates a constitutively active chimeric tyrosine kinase that signals through the TrkC receptor, activating Ras/MAPK, PI3K/AKT, and JAK/STAT pathways to drive uncontrolled proliferation, and is exquisitely sensitive to TrkA/B/C inhibition by larotrectinib and entrectinib. The foundational treatment paradigm for adult fibrosarcoma centers on wide surgical resection with histologically negative margins — achieved with limb-sparing surgery in the majority of extremity cases — supplemented by adjuvant radiation therapy for margin-positive or high-grade tumors and anthracycline-based systemic chemotherapy for locally advanced or metastatic presentations; for infantile fibrosarcoma, the paradigm has been transformed by the FDA approval of larotrectinib and entrectinib for NTRK fusion-positive solid tumors, with these agents producing deep and durable responses that frequently render previously unresectable tumors amenable to limb-sparing surgery and may allow deferred or avoided amputation in children with large congenital fibrosarcomas of the distal extremity. Pediatric oncologists managing NTRK inhibitor-based therapy for infantile fibrosarcoma, orthopedic surgical oncologists performing limb-sparing excision after NTRK inhibitor neoadjuvant therapy, medical oncologists managing anthracycline and ifosfamide chemotherapy for adult fibrosarcoma, radiation oncologists delivering adjuvant IMRT for adult fibrosarcoma, molecular pathologists performing ETV6-NTRK3 FISH and RNA-based fusion testing, pediatric surgeons coordinating limb salvage versus amputation decisions in infants with large distal extremity tumors, and investigators coordinating NTRK inhibitor trial programs together constitute the multidisciplinary care ecosystem for an entity that spans from a favorable-prognosis pediatric tumor responsive to targeted therapy to a molecularly heterogeneous adult sarcoma managed with traditional cytotoxic approaches.
Fibrosarcoma technology platforms — whether supporting pediatric oncology programs managing larotrectinib or entrectinib NTRK inhibitor therapy for ETV6-NTRK3-positive infantile fibrosarcoma (including dosing and cycle management, pediatric-specific adverse effect surveillance, tumor response monitoring by MRI, and treatment-to-surgery transition planning for limb-sparing procedures after neoadjuvant NTRK inhibitor response), orthopedic surgical oncology programs coordinating limb-sparing excision for extremity fibrosarcoma in both pediatric and adult patients (with intraoperative margin analysis, endoprosthetic reconstruction planning, and limb-function preservation strategy documentation), radiation oncology programs delivering adjuvant IMRT for adult fibrosarcoma (with margin-positive resection site coverage, critical structure sparing for peripheral nerve and vessel preservation, and limb-function dosimetry), medical oncology programs managing doxorubicin-based anthracycline chemotherapy for adult fibrosarcoma (with cumulative dose tracking and cardiac surveillance), ifosfamide management programs with hemorrhagic cystitis prevention protocols and mesna administration documentation, molecular diagnostics laboratories performing ETV6-NTRK3 FISH and RNA-based fusion panel testing for infantile fibrosarcoma confirmation and NTRK inhibitor eligibility, CDK4 amplification testing platforms for adult fibrosarcoma cases being evaluated for CDK4/6 inhibitor eligibility, multidisciplinary pediatric oncology tumor board coordination platforms integrating pediatric oncology, pediatric surgery, orthopedic surgery, and radiation oncology for limb-salvage planning in infants and young children, and patient and family portals supporting parents of pediatric fibrosarcoma patients through complex treatment decisions involving limb salvage versus amputation — must maintain the availability and performance standards that fibrosarcoma's molecular-targeted pediatric therapy, adult sarcoma chemotherapy management, and limb-salvage surgical complexity demands. This guide explains why fibrosarcoma tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the NTRK inhibitor management, anthracycline chemotherapy tracking, surgical limb-salvage planning, and molecular diagnostic depth of modern fibrosarcoma care.
Why Fibrosarcoma Tech Platforms Require Specialized Monitoring Attention
Fibrosarcoma management is defined by the sharp biological division between NTRK inhibitor-responsive infantile fibrosarcoma and anthracycline-treated adult fibrosarcoma, ETV6-NTRK3 molecular diagnostics for NTRK fusion confirmation and targeted therapy eligibility, limb-sparing surgical planning for pediatric and adult extremity tumors, NTRK inhibitor adverse effect management, adjuvant radiation for adult fibrosarcoma, anthracycline cumulative dose tracking with cardiac surveillance, and pediatric multidisciplinary coordination for limb salvage decisions. Technology failures in any of these areas create disruptions calibrated to the molecular diagnostic requirements, pediatric patient population, NTRK targeted therapy mechanisms, and limb-salvage surgical complexity unique to fibrosarcoma management.
ETV6-NTRK3 molecular diagnostics platforms determine NTRK inhibitor eligibility and guide the treatment paradigm. ETV6-NTRK3 fusion confirmation — by FISH demonstrating ETV6 rearrangement or NTRK3 rearrangement, or by RNA-based next-generation sequencing fusion panel detecting the ETV6::NTRK3 transcript — is the molecular test that confirms infantile fibrosarcoma diagnosis (differentiating it from other pediatric spindle-cell tumors), establishes larotrectinib or entrectinib eligibility, and guides the neoadjuvant therapy decision that will determine whether limb-sparing surgery is achievable without amputation. Platforms managing ETV6-NTRK3 FISH test ordering, RNA fusion panel result routing, NTRK inhibitor eligibility documentation, and clinical trial enrollment cannot fail during active diagnostic workup of pediatric fibrosarcoma. Monitor molecular diagnostics platforms at 1-minute intervals during business hours.
NTRK inhibitor management platforms coordinate targeted therapy with pediatric-specific dosing and surveillance. Larotrectinib (body-surface-area-based pediatric dosing, twice daily oral administration) and entrectinib (once-daily oral administration, approved for children ≥12 years with appropriate pediatric dosing) require platforms managing pediatric weight-based and BSA-based dosing records, treatment response monitoring by MRI (documenting tumor shrinkage that may allow deferred limb-sparing surgery), adverse effect surveillance (elevated liver enzymes, fatigue, dizziness, neurocognitive effects in pediatric patients), acquired resistance mutation monitoring (NTRK kinase domain mutations, MET amplification, alternative pathway activation), and transition planning documentation for surgery following neoadjuvant NTRK inhibitor response. Monitor NTRK inhibitor management platforms at 1-minute intervals during business hours.
Limb-sparing surgical planning platforms coordinate tumor response-to-surgery transitions for pediatric patients. Limb-sparing surgery following NTRK inhibitor neoadjuvant therapy for infantile fibrosarcoma — where tumor volume reduction of 50–80% following larotrectinib or entrectinib may transform a tumor requiring below-knee amputation into one amenable to wide local excision with functional limb preservation — requires platforms managing pre-NTRK-inhibitor and post-NTRK-inhibitor MRI volumetric comparison records, functional anatomy assessment documentation, intraoperative margin analysis routing, endoprosthetic or soft tissue reconstruction planning, and pediatric-specific limb-function outcome monitoring. Monitor surgical planning platforms at 1-minute intervals during business hours and operative windows.
Anthracycline chemotherapy management platforms require cumulative dose tracking for adult fibrosarcoma. Doxorubicin-based anthracycline chemotherapy for locally advanced or metastatic adult fibrosarcoma requires platforms managing cumulative anthracycline dose tracking (with cardiotoxicity monitoring, particularly in patients receiving second-line anthracycline), echocardiographic cardiac surveillance scheduling, ifosfamide dosing and mesna premedication protocol documentation, hemorrhagic cystitis prevention record documentation, and cycle timing records. Monitor anthracycline chemotherapy management platforms at 1-minute intervals during business hours and active administration sessions.
Adjuvant radiation platforms manage margin-positive adult fibrosarcoma with limb-function dosimetry. Adjuvant IMRT for adult fibrosarcoma — delivered to margin-positive or high-grade resection sites with field designs that must spare adjacent peripheral nerves, vessels, and skin to preserve limb function — requires platforms managing radiation treatment plan access, target volume and critical structure dose constraint documentation, daily delivery verification, and limb-toxicity surveillance. Monitor IMRT platforms at 1-minute intervals during active treatment sessions.
Pediatric multidisciplinary coordination platforms manage limb salvage versus amputation decisions. Fibrosarcoma in infants and young children — where the decision between limb-sparing excision (preserving growth plates, limb length, and functional extremity development across decades of childhood growth) and amputation (with pediatric prosthetic fitting and rehabilitation across a growing child's musculoskeletal development) involves pediatric oncology, orthopedic surgery, pediatric surgery, radiation oncology, and physical therapy collaboration — requires platforms supporting simultaneous multi-specialty record access, functional outcome documentation, growth plate imaging, and family counseling records. Monitor pediatric MDT coordination platforms at 1-minute intervals during business hours.
What to Monitor on a Fibrosarcoma Tech Platform
ETV6-NTRK3 and Molecular Diagnostics
Monitor ETV6-NTRK3 FISH rearrangement test ordering and result routing, RNA-based fusion panel result access for ETV6::NTRK3 transcript confirmation, NTRK inhibitor eligibility documentation, CDK4 amplification testing records for adult fibrosarcoma evaluation, and clinical trial enrollment documentation at 1-minute intervals during business hours. Alert immediately — molecular diagnostic failures delay NTRK fusion confirmation in a pediatric patient population where early NTRK inhibitor initiation determines whether limb-sparing surgery can be achieved without amputation.
NTRK Inhibitor Targeted Therapy Management
Monitor larotrectinib and entrectinib dosing records (pediatric weight-based and BSA-based dosing), MRI tumor response documentation (volumetric comparison to establish surgical eligibility), adverse effect surveillance records (hepatotoxicity, neurologic effects, fatigue), acquired resistance mutation testing records, dose modification and interruption documentation, and surgical transition planning records at 1-minute intervals during business hours. Alert immediately — NTRK inhibitor management failures delay monitoring of pediatric adverse effects and tumor response documentation that determines surgical planning decisions.
Limb-Sparing Surgical Planning
Monitor pre- and post-treatment MRI volumetric comparison records, intraoperative frozen section margin routing and result communication, endoprosthetic and soft tissue reconstruction planning records, pediatric growth plate documentation and impact assessment, limb-function outcome records, and post-operative rehabilitation coordination at 1-minute intervals during business hours and operative windows. Alert immediately during active operative margin analysis.
Anthracycline Chemotherapy Management
Monitor cumulative doxorubicin dose tracking records, echocardiographic cardiac surveillance scheduling and result documentation, ifosfamide dosing and mesna premedication protocol records, hemorrhagic cystitis prevention documentation (hyperhydration, urinalysis surveillance), cycle timing and dose reduction documentation, and myelosuppression toxicity records at 1-minute intervals during business hours and active administration sessions. Alert immediately during active chemotherapy administration.
Adjuvant Radiation Management
Monitor IMRT treatment plan access and field modification records, target volume and critical structure dose constraint documentation (peripheral nerve, vessel, skin sparing for limb function preservation), daily delivery verification, acute toxicity surveillance, and treatment completion documentation at 1-minute intervals during active treatment sessions. Alert immediately during active delivery.
Pediatric Multidisciplinary Tumor Board Coordination
Monitor MDT case presentation record access across pediatric oncology, orthopedic surgery, pediatric surgery, radiation oncology, and physical therapy, imaging and pathology report synchronization, limb salvage versus amputation decision documentation, family counseling record access, growth plate and functional anatomy assessment records, and treatment plan modification records at 1-minute intervals during business hours. Alert immediately during scheduled pediatric tumor board sessions.
Patient and Family Communication Portal
Monitor patient and family portal availability for pediatric toxicity reporting, NTRK inhibitor home administration guidance access, appointment coordination, treatment response update communication, and care team messaging during active treatment and surgical transition phases. Alert on sustained failures during business and evening hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Fibrosarcoma programs coordinate across pediatric oncology, pediatric surgery, orthopedic surgical oncology, radiation oncology, medical oncology, and molecular pathology — authentication failures simultaneously block every member of a multidisciplinary team managing pediatric patients whose NTRK inhibitor response documentation, MRI tumor response records, and surgical planning records must be simultaneously accessible across specialties coordinating limb salvage decisions in a pediatric population where treatment timing is critical to functional outcome.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across all patient and family portals, surgical planning systems, radiation delivery platforms, NTRK inhibitor management systems, molecular diagnostics interfaces, anthracycline management platforms, and tumor board coordination tools. Certificate errors disrupt the molecular diagnostic and treatment management workflows central to fibrosarcoma care.
HIPAA and Oncology Data Privacy Considerations
Fibrosarcoma technology platforms handle sensitive PHI including ETV6-NTRK3 fusion test results with implications for NTRK inhibitor therapy eligibility and pediatric tumor prognosis, larotrectinib and entrectinib treatment records in pediatric patients (with heightened privacy protections applicable to minor patients), limb salvage versus amputation decision documentation involving sensitive functional and quality-of-life deliberations for pediatric patients and families, cumulative anthracycline dose tracking records with cardiac surveillance implications for adult fibrosarcoma patients, IMRT treatment records, and pediatric multidisciplinary tumor board deliberation records encompassing sensitive pediatric surgical risk, growth impact, and long-term functional outcome discussions. HIPAA Privacy Rule protections for minor patients require heightened access control standards for pediatric fibrosarcoma records, with appropriate parental authorization workflows and age-appropriate patient engagement documentation as children transition through adolescence.
For platforms managing pediatric NTRK inhibitor treatment records — where the treatment program spans months to years of larotrectinib therapy preceding and following limb-sparing surgery — data continuity and availability standards must reflect the longitudinal nature of pediatric NTRK inhibitor management. For platforms managing adult fibrosarcoma anthracycline dose tracking records where cumulative cardiotoxicity documentation informs long-term cardiac surveillance across years of survivorship, availability standards must match the patient safety dependency of these records for cancer survivors at risk of late cardiac complications. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for fibrosarcoma programs managing sensitive pediatric and adult oncology PHI.
Alerting Strategy for Fibrosarcoma Tech Platforms
Immediate alerting 24/7: Authentication and core platform access. Pediatric fibrosarcoma patients on NTRK inhibitor therapy may require urgent care team access outside business hours for adverse effect management.
Immediate alerting during treatment sessions: IMRT planning and delivery platforms during active radiation sessions; anthracycline and ifosfamide chemotherapy management during active administration. These platforms cannot fail without immediate clinical intervention.
Immediate business-hours alert: ETV6-NTRK3 molecular diagnostics (NTRK fusion confirmation and targeted therapy eligibility), NTRK inhibitor management during active pediatric treatment and surveillance cycles, limb-sparing surgical planning during preoperative and operative windows, pediatric multidisciplinary tumor board coordination, and CDK4 molecular diagnostics for adult fibrosarcoma evaluation. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Patient and family communication portal, post-treatment surveillance imaging scheduling, and long-term recurrence monitoring. Alert when failures persist beyond a single workflow cycle.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms fibrosarcoma platform availability from the geographies where pediatric oncology specialist centers, orthopedic surgical oncology programs, radiation oncology departments, and infusion suites access the system — important for platforms supporting pediatric patients and families who travel to specialist centers for NTRK inhibitor therapy initiation or limb-sparing surgical planning and return to regional institutions for ongoing management.
Status Page for Fibrosarcoma Care Team Communication
A real-time status page gives pediatric oncologists managing NTRK inhibitor dosing and tumor response monitoring, orthopedic surgeons coordinating limb-sparing excision following neoadjuvant NTRK inhibitor response, medical oncologists managing doxorubicin/ifosfamide chemotherapy for adult fibrosarcoma, radiation oncologists delivering adjuvant IMRT, molecular pathologists routing ETV6-NTRK3 fusion results, and multidisciplinary tumor board coordinators managing pediatric limb salvage decisions immediate platform visibility without requiring inbound IT support contact. During a molecular diagnostics platform outage during active ETV6-NTRK3 fusion result routing for an infant presenting with a large congenital distal extremity fibrosarcoma where NTRK fusion confirmation is required before initiating larotrectinib, a status page enables the molecular pathology and pediatric oncology teams to immediately activate emergency diagnostic access protocols and communicate the delay to the family and surgical planning team.
Include the status page URL in ETV6-NTRK3 molecular diagnostic downtime procedures, NTRK inhibitor management fallback protocols, pediatric MDT coordination emergency workflows, anthracycline administration downtime procedures, and limb-sparing surgical planning contingency workflows.
Vigilmon Setup for Fibrosarcoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ETV6-NTRK3 / molecular diagnostics | 1 min | Slack + PagerDuty (business hours) | | NTRK inhibitor management (larotrectinib / entrectinib) | 1 min | Slack + PagerDuty (business hours) | | Limb-sparing surgical planning (operative hours) | 1 min | Slack + PagerDuty (surgical hours) | | Anthracycline chemotherapy management (treatment sessions) | 1 min | Slack + PagerDuty (treatment hours) | | Adjuvant IMRT planning and delivery (treatment sessions) | 1 min | Slack + PagerDuty (treatment hours) | | Pediatric multidisciplinary tumor board coordination | 1 min | Slack + PagerDuty (business hours) | | Patient / family communication portal | 2 min | Slack (business + evening hours) | | Post-treatment surveillance imaging | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ETV6-NTRK3 and molecular diagnostics platforms with immediate business-hours alerting
- Add NTRK inhibitor management (larotrectinib/entrectinib) with immediate business-hours alerting for pediatric dosing and adverse effect surveillance
- Configure limb-sparing surgical planning with immediate alerting during operative windows
- Add anthracycline chemotherapy management with immediate alerting during active administration sessions
- Configure adjuvant IMRT planning and delivery with immediate alerting during active treatment sessions
- Add pediatric multidisciplinary tumor board coordination with immediate alerting during scheduled MDT sessions
- Configure patient and family communication portal monitoring for NTRK inhibitor home administration guidance and toxicity reporting
- Add post-treatment surveillance imaging scheduling with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, patient-facing, surgical planning, IMRT, NTRK inhibitor management, and molecular diagnostics domains
- Add the status page URL to ETV6-NTRK3 molecular diagnostic downtime procedures, NTRK inhibitor fallback protocols, and pediatric MDT emergency access workflows
Conclusion
Fibrosarcoma technology platforms are embedded in clinical decisions where molecular diagnostics platform availability during active ETV6-NTRK3 fusion result routing for an eight-month-old infant presenting with a 7-centimeter congenital fibrosarcoma of the foot determines whether the pediatric oncologist can access the RNA fusion panel result confirming the ETV6::NTRK3 transcript that establishes larotrectinib eligibility, review the prior MRI documentation that quantifies the tumor's relationship to the growth plate and metatarsal bones of the developing foot, and initiate the NTRK inhibitor therapy that, in historical cohorts of infantile fibrosarcoma, reduces tumor volume by 50–80% over 8–16 weeks and may transform a presentation requiring transmetatarsal amputation into one allowing limb-sparing excision with preservation of the foot and normal ambulatory development throughout childhood — where NTRK inhibitor management platform availability during active larotrectinib treatment and MRI response monitoring determines whether the pediatric oncologist can access the volumetric response documentation showing progressive tumor shrinkage that has reached the threshold required to bring the case to the multidisciplinary tumor board for limb-sparing surgical planning, the adverse effect surveillance records documenting liver enzyme trends that will inform dose modification decisions, and the family communication records that ensure the parents of a pediatric patient understand the treatment response trajectory and the surgical transition plan — and where anthracycline chemotherapy management platform availability during active doxorubicin administration for an adult with locally advanced fibrosarcoma of the thigh determines whether the oncologist coordinating the fourth cycle of doxorubicin/ifosfamide can access the cumulative anthracycline dose record that documents the patient is approaching the threshold requiring echocardiographic cardiac re-evaluation, the mesna premedication protocol that prevents hemorrhagic cystitis during ifosfamide exposure, and the prior cycle toxicity records that inform the dose modification decision for a patient with Grade 3 neutropenia on prior cycle. A molecular diagnostics platform inaccessible when ETV6-NTRK3 fusion confirmation is required before initiating the NTRK inhibitor therapy that may prevent limb amputation in an infant, an NTRK inhibitor management platform unavailable when MRI tumor response documentation must be accessed to make the surgical transition decision that determines whether limb-sparing surgery has become technically feasible, an anthracycline chemotherapy management platform inaccessible when cumulative dose tracking is required to make the cardiac safety decision that protects an adult fibrosarcoma patient from anthracycline cardiotoxicity — these are not IT incidents. They are clinical disruptions in the management of a biologically bifurcated sarcoma entity where platform availability shapes the molecular diagnostic access that enables targeted therapy initiation, the NTRK inhibitor response monitoring that determines surgical eligibility, and the anthracycline dose tracking that protects long-term cardiac function in patients who survive their fibrosarcoma.
Uptime monitoring gives fibrosarcoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pediatric oncology programs, orthopedic surgical oncology departments, radiation oncology programs, and compliance auditors that the platform's operational reliability matches the molecular diagnostic precision, NTRK targeted therapy management, pediatric limb-salvage surgical complexity, and anthracycline chemotherapy tracking of modern fibrosarcoma care.
Start monitoring your fibrosarcoma tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #fibrosarcoma #infantilefibrosarcoma #congenitalfibrosarcoma #ETV6NTRK3 #NTRKfusion #larotrectinib #entrectinib #NTRKinhibitor #adultsarcoma #CDK4 #anthracycline #ifosfamide #limbsalvage #IMRT #pediatriconcology #moleculardiagnostics #multidisciplinaryoncology #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre